anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Celecoxib
Trial phase: Not Applicable
ATC code: C08CA51 | G01AE10 | L01XX33 | M01AH01 | N02AJ16
SMILES: Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Celecoxib, 200 mg tab

Celecoxib: 200 mg tablet oral
Eligibility criteria:
Inclusion Criteria:

- Colon cancer patients with no evidence of metastasis in distant organs (i.e., TNM stage I-III), who are

between 18 and 75 years old,
have a body mass index (BMI) between 18 and 35 kg/m^2,
and are eligible for laparoscopically-assisted colectomy for primary tumor resection.
Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

- A history of allergic-type reactions to celecoxib or sulphonamides,

a history of asthma, skin reactions or other allergic reactions to aspirin or other NSAIDs,
a history of thromboembolic event (cerebrovascular accident, transient ischemic attack,
unstable angina, myocardial infarction, deep vein thrombosis, or pulmonary embolism),
renal insufficiency (defined by a serum creatinine level > 1.5 mg/dL or blood urea nitrogen level > 22 mg/dL),
active gastrointestinal bleeding in the 60 days before surgery,
alcohol or drug abuse, and
previous chemotherapy or abdominal/pelvic radiation therapy.
After randomization, other exclusion criteria will include a surgical procedure longer than 6 h, inability to extubate the trachea within 4 h after operation, evidence of a new postoperative myocardial infarction, abnormal postoperative mental status or any new neurologic deficit, significant postoperative bleeding (with a hemoglobin level < 7.5 g/dL), requiring blood transfusion, or a urine output of less than 30 mL/h.
Intervention: Risperidone
Trial phase: Phase 4
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Drug: risperidone Groups: risperidone
Eligibility criteria:
Inclusion Criteria:

Aged 18-38 years and meet no DSM-IV diagnostic criteria as assessed by using the Structured Clinical Interview for DSM-IV, research version

Exclusion Criteria:

Anyone who:

Participated in other clinical trials within 30 days from the start of this clinical trial or is currently participating in one
Has progressive disease or in unstable medical condition unfit for the trial
Has been diagnosed in psychiatric terms in the past, depends on psychotropic substance, or has overdosed or depended on the substance or alcohol (except for coffee or tobacco) within 1 month from the trial start
Is suicidal or highly probable of suicides; OR
Has test results considered clinically meaningful
Intervention: Paliperidone
Trial phase: Phase 4
ATC code: N05AX13
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Drug: Paliperidone ER Groups: Paliperidone ER
Eligibility criteria:
Inclusion Criteria:

Aged 18-38 years and meet no DSM-IV diagnostic criteria as assessed by using the Structured Clinical Interview for DSM-IV, research version

Exclusion Criteria:

Anyone who:

Participated in other clinical trials within 30 days from the start of this clinical trial or is currently participating in one
Has progressive disease or in unstable medical condition unfit for the trial
Has been diagnosed in psychiatric terms in the past, depends on psychotropic substance, or has overdosed or depended on the substance or alcohol (except for coffee or tobacco) within 1 month from the trial start
Is suicidal or highly probable of suicides; OR
Has test results considered clinically meaningful
Intervention: Utibron Neohaler
Trial phase: Phase 3
SMILES: CCc1cc2c(cc1CC)CC(NCC(O)c1ccc(O)c3[nH]c(=O)ccc13)C2.C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 119
Group description: QVA149 110/50 μg once a day (o.d)
Eligibility criteria:
Inclusion Criteria:

Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)
Patients with post-bronchodilator forced expiratory volume in one second (FEV1) ≥30% and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) < 0.7 at Visit 2.

Exclusion Criteria:

Pregnant women or nursing mothers or women of child-bearing potential not using an acceptable method of contraception
Patients requiring long term oxygen therapy
Patients who have had a lower respiratory tract infection within 4 weeks prior to Visit 1
Patients with concomitant pulmonary disease
Patients with a history of asthma
Any patient with history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years
Patients with a history of certain cardiovascular comorbid conditions
Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
Patients in the active phase of a supervised pulmonary rehabilitation program
Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, sympathomimetic amines

Other protocol-defined inclusion/exclusion criteria may apply
Intervention: Tiotropium
Trial phase: Phase 3
ATC code: R03AL06 | R03AL10 | R03BB04 | R03BB54
SMILES: [H][C@]1(OC(=O)C(O)(c2cccs2)c2cccs2)C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: tiotropium 18 μg o.d.
Eligibility criteria:
Inclusion Criteria:

Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
Current or ex-smokers who have a smoking history of at least 10 pack years. (Ten pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.)
Patients with post-bronchodilator forced expiratory volume in one second (FEV1) ≥30% and < 80% of the predicted normal, and post-bronchodilator FEV1/forced vital capacity (FVC) < 0.7 at Visit 2.

Exclusion Criteria:

Pregnant women or nursing mothers or women of child-bearing potential not using an acceptable method of contraception
Patients requiring long term oxygen therapy
Patients who have had a lower respiratory tract infection within 4 weeks prior to Visit 1
Patients with concomitant pulmonary disease
Patients with a history of asthma
Any patient with history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years
Patients with a history of certain cardiovascular comorbid conditions
Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
Patients in the active phase of a supervised pulmonary rehabilitation program
Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, sympathomimetic amines

Other protocol-defined inclusion/exclusion criteria may apply
Intervention: Bivalirudin
Trial phase: Phase 2
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 83
Group description: 10cc/kg NS, followed by 30cc/kg NS
Eligibility criteria:
Inclusion Criteria:

Males or females age 2 months to 12th birth date
Gastroenteritis (as diagnosed by ED attending or fellow physician)
Need for IV fluids
Dextrose stick of greater than 60 and less than 170
Parental/guardian English speaking and granting informed consent

Exclusion Criteria:

Underlying chronic disease affecting glucose metabolism or reason/persistence of symptoms: Renal failure, Diabetes Mellitus, Diabetes Insipidus, Metabolic Disorder, VP shunt, Migraine Headaches
Shock
Vomiting greater than 72 hours since onset of illness
Patients that have received IV fluids at an outside institution within 12 hours
Intervention: Disulfiram
Trial phase: Not Applicable
ATC code: N07BB01 | P03AA04 | P03AA54
SMILES: CCN(CC)C(=S)SSC(=S)N(CC)CC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: Disulfiram: Open label 500mg disulfiram per day by mouth for 14 days
Eligibility criteria:
Inclusion Criteria:

Documented continuous HAART for at least 18 months prior to study entry and on a stable regimen for at least 3 months prior to entry.
Documented undetectable HIV viral loads for at least one year. Intermittent isolated episodes of detectable low-level viremia "blips" (> 50 but < 500 copies RNA/mL) remain eligible.
Screening plasma HIV-1 RNA levels < 40 copies RNA/mL.
CD4 T-cell count above 200 cells/uL for 24 weeks prior to screen.
>90% adherence to therapy within the preceding 30 days.
Females of childbearing potential must have a negative serum pregnancy test at screening and agree to use a double-barrier method of contraception throughout the study period.
Willing to abstain from any alcohol during the two week period in which disulfiram will be administered and during the two week period immediately after disulfiram administration.

Exclusion Criteria:

Current alcohol use disorder or hazardous alcohol use as determined by clinical evaluation.
Current use of any drug formulation that contains alcohol or that might contain alcohol.
Current use of tipranavir.
Current use of maraviroc.
Current use of warfarin.
Intending to modify antiretroviral therapy in the next 27 weeks for any reason.
Serious illness requiring hospitalization or parental antibiotics within preceding 3 months.
Severe myocardial disease or coronary artery disease.
History of psychosis.
Clinically active hepatitis determined by the study physician; ALT or AST >3 x the upper limit of normal.
Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drug in past 16 weeks.
Pregnant or breastfeeding women.
Intervention: Vancomycin
Trial phase: Phase 4
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Vancomycin vs. daptomycin: Vancomycin dosed to achieve a trough of 15-20 microgram/mL vs. daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Signed informed consent
All cases of suspected MRSA bacteremia as determined by a patient with at least one blood culture growing gram-positive cocci in clusters with a clinical syndrome consistent with true bacteremia including fever, hypothermia (temperature < 36.0º C), tachycardia (heart rate > 100 beats/minute), hypotension (systolic blood pressure < 90 mm Hg) or other clinical features of sepsis.
All cases of right-sided native valve endocarditis due to MRSA
Patients who are diagnosed with left-sided native valve endocarditis after randomization will be continued in the study
Patients with MRSA bacteremia associated with infected foreign bodies, including vascular prostheses, orthopedic prostheses
Intervention: Daptomycin
Trial phase: Phase 4
ATC code: J01XX09
SMILES: CCCCCCCCCC(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC1C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CO)C(=O)NC(C(C)CC(=O)O)C(=O)NC(CC(=O)c2ccccc2N)C(=O)OC1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Vancomycin vs. daptomycin: Vancomycin dosed to achieve a trough of 15-20 microgram/mL vs. daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Signed informed consent
All cases of suspected MRSA bacteremia as determined by a patient with at least one blood culture growing gram-positive cocci in clusters with a clinical syndrome consistent with true bacteremia including fever, hypothermia (temperature < 36.0º C), tachycardia (heart rate > 100 beats/minute), hypotension (systolic blood pressure < 90 mm Hg) or other clinical features of sepsis.
All cases of right-sided native valve endocarditis due to MRSA
Patients who are diagnosed with left-sided native valve endocarditis after randomization will be continued in the study
Patients with MRSA bacteremia associated with infected foreign bodies, including vascular prostheses, orthopedic prostheses
Intervention: Acetazolamide
Trial phase: Not Applicable
ATC code: G01AE10 | S01EC01
SMILES: CC(=O)Nc1nnc(S(N)(=O)=O)s1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
Eligibility criteria:
Inclusion Criteria:

Member of the Italian High Altitude Research Expeditions

Exclusion Criteria:

Are under the age of 18years;
sulfonamide allergy
Liver or kidney disfunction
Have any other uncontrolled medical condition
Or are unable to give consent.
Intervention: Lactose monohydrate
Trial phase: Not Applicable
SMILES: O.OCC1OC(OC2C(CO)OC(O)C(O)C2O)C(O)C(O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
Eligibility criteria:
Inclusion Criteria:

Member of the Italian High Altitude Research Expeditions

Exclusion Criteria:

Are under the age of 18years;
sulfonamide allergy
Liver or kidney disfunction
Have any other uncontrolled medical condition
Or are unable to give consent.
Intervention: Milnacipran
Trial phase: Phase 4
ATC code: N06AX17 | N06AX28
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Titrated Milnacipram doses

Milnacipram: Titration to 200mg PO daily
Eligibility criteria:
Inclusion Criteria:

Female age 18 or older
Written informed consent and written release of health and research study information
Diagnosis of Fibromyalgia
Participant has pain greater than 4 on the NRS of 0 to 10 on average over the last week prior to initial evaluation that interferes with function most days per week
Pain duration greater than 6 months
Negative urine pregnancy test on experimental day 1 and 2 and on first day of treatment prior to administration of study medication and fluoroscopy
Ability to speak and understand English, to follow instructions, and fill out study questionnaires
Likely to complete all required visits
Must be ambulatory and able to lay prone for 30 minutes

Exclusion Criteria:

Any condition or situation that in the investigator's opinion may put the participant at significant risk, confound the study results, or interfere significantly with the participant's participation in the study
Serious, unstable medical illness that could lead to hospitalization over the next three months; and/or a DSM-IV diagnosis(es) with active problems within the last six months, such as: schizophrenia, bipolar disorder, antisocial personality disorder, or substance use disorder
Known, uncontrolled, serious systemic disease, including: hypertension and/or tachyarrythmia
Females who are pregnant, breast feeding, or who plan to become pregnant, or who may potentially become pregnant
Allergy or sensitivity to any component of the study medication or to contrast dye
Patients on coumadin, heparin, or any other known increase risk of bleeding
Signs of increased intracranial pressure
Patients who are unable to continue current pain medication
Allergy or contraindication to acetaminophen
Use of monoamine oxidase inhibitors
Uncontrolled narrow-angle glaucoma
Intervention: Milnacipran
Trial phase: Phase 3
ATC code: N06AX17 | N06AX28
SMILES: CCN(CC)C(=O)C1(c2ccccc2)CC1CN
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):

Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)
Eligibility criteria:
Inclusion Criteria:

Male and female patients age 18 to 80 years
Patients with signs and symptoms of a peripheral neuropathy, with either abnormal nerve conductions or abnormal epidermal nerve fiber density with neuropathic pain.
Pain will have been present for at least 6 months
Patients may be on other medications for neuropathic pain (eg, antiepileptic medications, opiates or non steroidal antiinflammatories); however they must be on a stable dose for 4 weeks prior to, with no plan to change during the study
All patients must have had a normal fasting glucose or B12, thyroid stimulating hormone, and serum protein electrophoresis, since the onset of their symptoms.

Exclusion Criteria:

Other cause of neuropathy (eg, diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy)
Unstable angina
Use of another serotonin and norepinephrine reuptake inhibitors (eg, duloxetine, venlafaxine), tricyclic antidepressants, monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors
Myocardial infarction stroke or life threatening arrhythmia within the last 6 months
HIV infection
Hepatic or renal failure
Pregnancy
narrow angle glaucoma
History of epilepsy or a seizure
Intervention: Satraplatin
Trial phase: Phase 2
ATC code: L01XA04
SMILES: CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Satraplatin: Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
Eligibility criteria:
Inclusion Criteria:

Patients must have histologically confirmed adenocarcinoma of the prostate.
Radiographic evidence of metastatic disease (Bone scan, CT(Computerized Tomography) scan, or MRI(Magnetic Resonance Imaging) are acceptable) amenable to image-guided biopsy.
Castrate levels of testosterone (testosterone <50 ng/dL) on androgen deprivation therapy (ADT). LHRH(luteinizing hormone releasing hormone)agonist therapy must continue while on study unless patient has previously undergone an orchiectomy.
The patient must have discontinued antiandrogens (bicalutamide, flutamide or nilutamide) 30 days prior to baseline PSA.
Progression on at least one line of a prior docetaxel-based chemotherapy.

Patients must have adequate organ and marrow function as defined below:

Absolute neutrophil count >1,500/μl
Platelets >100,000/μl
GFR(glomerular Filtration Rate) >30 ml/min
ALT(Alanine transaminase) and AST(Aspartate transaminase) ≤ 2.5 X upper limit of normal (ULN) or ≤ 5 X ULN in patients with liver metastasis
Age > 18 years
Ability to take oral medications (pills must be swallowed whole)
ECOG (Eastern Cooperative Oncology Group) performance status 0-2
Ability to understand and the willingness to sign a written informed consent document
Patients must be willing to undergo an image-guided biopsy of a metastatic site on at least one occasion.
Patient agrees to utilize contraception while enrolled in the trial

Exclusion Criteria:

Patients who have received prior treatment with a platinum chemotherapy.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (requiring antifungal, antibiotic or antiviral therapy), history of symptomatic congestive heart failure (NYHC (New York Heart Association Classification) III), unstable angina pectoris, cardiac arrhythmia (uncontrolled SVT(Super ventricular tachycardia)or any VT(ventricular tachycardia), or psychiatric illness/social situations that would limit compliance with study requirements.
Patients with a medical contraindication to image-guided biopsies
Patients with a severe allergic reaction to satraplatin compounds.
Has a history of a prior malignancy with the exception of the following: adequately treated basal cell or squamous cell skin cancer, or other cancers for which the subject has been disease-free for at least 5 years.
Has had radiation therapy within 30 days prior to being registered for protocol therapy.
Intervention: Alogliptin
Trial phase: Phase 3
ATC code: A10BD09 | A10BD13 | A10BH04
SMILES: Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 92
Group description: Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
Eligibility criteria:
Inclusion Criteria:

Has a historical diagnosis of Type 2 Diabetes Mellitus.
Has a body mass index between acceptable range.
Is experiencing inadequate glycemic control.
Body weight keeps constant.
Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.

Exclusion Criteria:

Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.
Has a systolic blood pressure beyond the acceptable range at Screening visit.
Has New York Heart Association Class III or IV heart failure regardless of therapy.
Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.
Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.
Intervention: Carboplatin
Trial phase: Phase 1 | Phase 2
ATC code: L01XA02
SMILES: [H]N([H])([H])->[Pt]1(<-N([H])([H])[H])OC(=O)C2(CCC2)C(=O)O1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 92
Group description: Concurrent Carboplatin and Radiotherapy

Carboplatin: IV, weekly for 6 weeks, AUC of 2.0

3D-RT or IMRT: From week 2 to week 4 in the 6-week Carboplatin treatment: Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy
Eligibility criteria:
Inclusion Criteria:

Age older than 18
Pre- or post-menopausal women with Stage I and II breast cancer, triple negative tumors
Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (Tumors < 5 mm in size do not require nodal assessment) or after mastectomy
No previous chemotherapy
Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document

Exclusion Criteria:

Previous radiation therapy to the ipsilateral breast
Active connective tissue disorders, such as lupus or scleroderma
Pregnant or lactating women